Investors
argenx is a global immunology company developing antibody-based medicines for patients suffering from severe autoimmune diseases and cancer. By translating immunology breakthroughs into innovative drug candidates, argenx is building a world-class portfolio of first-in-class antibodies in both early and late clinical-stages of development.
argenx is evaluating its lead candidate, efgartigimod, in multiple serious autoimmune indications and cusatuzumab in hematological malignancies in collaboration with Janssen, along with advancing earlier stage assets within its therapeutic franchises.
Investor materials
Corporate Presentation
Financial Results
Annual Reports
Corporate Governance
Shareholder Meetings
Analyst Coverage
Click below to see the complete list of covering analysts.
SEC Filings
Click below to search for argenx SEC filings.
Stock information
Press Releases
Press releases pertaining to argenx stock, financial information and investments.
